Abstract
Background Surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections is essential for the global containment measures with regard to the ongoing pandemic. Diagnostic gold standard is currently reverse transcription of the (+)RNA genome and subgenomic RNAs and subsequent quantitative polymerase chain reaction (RT-qPCR) from nasopharyngeal swabs or bronchoalveolar lavages. In order to further improve the diagnostic accuracy, particularly for the reliable discrimination between negative and false-negative specimens, we propose the combination of the RT-qPCR workflow with subsequent pyrosequencing of a S-gene amplicon. This extension might add important value mainly in cases with low SARS-CoV-2 load, where RT-qPCR alone can deliver conflicting results.s
Results We successfully established a combined RT-qPCR and S-gene pyrosequencing method which can be optionally exploited after routine diagnostics or for epidemiologic studies. This allows a more reliable interpretation of conflicting RT-qPCR results in specimens with relatively low viral loads and close to the detection limits of qPCR (CT values >30). After laboratory implementation and characterization of a best practice protocol we tested the combined method in a large pediatric cohort from two German medical centers (n=769). Pyrosequencing after RT-qPCR enabled us to uncover 6 previously unrecognized cases of pediatric SARS-CoV-2 associated diseases, partially exhibiting unusual and heterogeneous presentation. Moreover, it is notable that in the course of RT-qPCR/pyrosequencing method establishment we did not observe any case of false-positive diagnosis when confirmed SARS-CoV-2-positive specimens were used from foregoing routine testing.
Conclusions The proposed protocol allows a specific and sensitive detection of SARS-CoV-2 close to the detection limits of RT-qPCR. Combined RT-qPCR/pyrosequencing does not negatively affect preceding RT-qPCR pipeline in SARS-CoV-2 diagnostics and can be optionally applied in routine to inspect conflicting RT-qPCR results.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was financed by own institutional means.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the collection and use of specimens at Helios University Hospital Wuppertal (North Rhine-Westphalia, Western Germany) and Klinikum Kassel (Hessen, Central Germany) with obtained approval of the Witten/Herdecke University Ethics board (covered by No. 61/2020 [CoronaKids] and No. 160/2020 for the use of routinely sampled and confirmed specimens for RT-qPCR/pyrosequencing method establishment). All work has been conducted according to the principles expressed in the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-Mail addresses: Patrick Philipp Weil: patrick.weil{at}uni-wh.de, Jacqueline Hentschel: jacqueline-hentschel{at}web.de, Frank Schult: frank.schult{at}helios-gesundheit.de, Anton Pembaur: anton.pembaur{at}uni-wh.de, Beniam Ghebremedhin: beniam.ghebremedhin{at}helios-gesundheit.de, Olivier Mboma: olivier.mboma{at}helios-gesundheit.de, Andreas Heusch: andreas.heusch{at}helios-gesundheit.de, Anna-Christin Reuter: anna.christin.reuter{at}googlemail.com, Daniel Müller: daniel_mueller_en{at}freenet.de, Stefan Wirth: stefan.wirth{at}helios-gesundheit.de, Malik Aydin: malik.aydin{at}uni-wh.de, Andreas C. W. Jenke: andreas.jenke{at}gnh.net
Data Availability
Not applicable
List of abbreviations
- (+)RNA
- sense polarity [single-stranded] ribonucleic acid
- CI
- confidence interval
- COVID-19
- coronavirus disease 2019
- MERS
- Middle East respiratory syndrome
- CT
- cycle threshold
- ORF
- open reading frame
- RdRP
- RNA-dependent RNA polymerase
- RT-qPCR
- reverse transcription-quantitative polymerase chain reaction
- SARS-CoV-1
- SARS-CoV-2 (severe acute respiratory syndrome coronavirus 1
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- sgRNA
- subgenomic RNA
- Taq
- Thermus aquaticus